- 08/28/2019
- EISAI ENTERS INTO BUSINESS ALLIANCE WITH COGSTATE FOR EXCLUSIVE DEVELOPMENT AND COMMERCIALIZATION OF A DIGITAL TOOL FOR SELF-ASSESSMENT OF COGNITIVE FUNCTION IN JAPAN
- 08/27/2019
- EISAI PROVIDES TANKS TO SUPPLY CLEAN WATER TO NEGLECTED TROPICAL DISEASES ENDEMIC REGIONS IN KENYA, IN COLLABORATION WITH MERCK
- 07/23/2019
- Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Breakthrough Therapy Designation from FDA for LENVIMA® (lenvatinib) plus KEYTRUDA® (pembrolizumab) Combination Treatment
- 07/19/2019
- LATEST TRENDS OF TREATMENT FOR ALZHEIMER’S DISEASE IN SESSIONS AND SYMPOSIUM AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2019
- 07/19/2019
- EISAI PRESENTS DATA SHOWING QUANTIFICATION OF TAU MICROTUBULE BINDING REGION IN CEREBROSPINAL FLUID AND THE IDENTIFICATION OF A TARGET ENGAGEMENT BIOMARKER FOR THE NEW ANTI-TAU ANTIBODY E2814 AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC)2019
- 07/18/2019
- EISAI PRESENTS RESEARCH EVALUATING CORRELATION OF HIGHLY-PRECISELY MEASURED AMYLOID BETA IN PLASMA AND CEREBROSPINAL FLUID WITH NEWLY DEVELOPED AUTOMATED PROTEIN ASSAY SYSTEM AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2019
- 07/18/2019
- EISAI PRESENTS NONCLINICAL RESEARCH RESULTS OF ELENBECESTAT OF WITHOUT SIGNIFICANT EFFECTS ON SYNAPTIC FUNCTION IN BRAIN BY SPINAL DENSITIY EVALUATION AT EFFECTIVE DOSE TO DECREASE AMYLOID BETA LEVEL IN CEREBROSPINAL FLUID AT AAIC 2019
- 07/17/2019
- ANTICANCER AGENT ERIBULIN MESYLATE APPROVED FOR TREATMENT OF LOCALLY ADVANCED OR METASTATIC BREAST CANCER IN CHINA
- 07/11/2019
- EISAI LISTED FOR 18TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT
- 07/10/2019
- EISAI CENTER FOR GENETICS GUIDED DEMENTIA DISCOVERY COMMENCES FULL-SCALE OPERATION TOWARD INNOVATIVE DEMENTIA TREATMENTS WITH NEW DRUG DISCOVERY APPROACH IN CAMBRIDGE, MASSACHUSETTS
